# Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

> **NCT03591224** · NA · COMPLETED · sponsor: **John Papastergiou Pharmacy Ltd** · enrollment: 213 (actual)

## Conditions studied

- Depression
- Anxiety
- Major Depressive Disorder
- Generalized Anxiety Disorder
- Mood Disorders

## Interventions

- **OTHER:** Pharmacogenomic Testing
- **OTHER:** Pharmacist Standard of Care

## Key facts

- **NCT ID:** NCT03591224
- **Lead sponsor:** John Papastergiou Pharmacy Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03591224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03591224, "Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03591224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*